A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)

NCT07208149 ↗

Phase 1/2 Recruiting 42 enrolled Shenzhen Majory Biotechnology Co., Ltd.

Non-randomizedSequentialOpen-labelTreatment

Summary

This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 in patients with advanced triple-negative breast cancer (TNBC) who have progressed after prior therapy.

Timeline

Start: 2026-01-29
Primary completion: 2028-09-01
Completion: 2028-09-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MR001	Unknown	1 mg/kg	Intravenous
Subject	MR001	Unknown	2 mg/kg	Intravenous
Subject	MR001	Unknown	4 mg/kg	Intravenous

A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)

Summary

Timeline

Drugs

Indications